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Abstract. Several opioid agonists and antagonists interact 
with N,N-dimethyltryptamine (DMT) and lysergic acid 
diethylamide-25 (LSD) in adult male Hottzman rats trained 
on a positive reinforcement, fixed ratio 4 (FR4) behavioral 
schedule, i.e., a reward of 0.01 ml sugar-sweetened milk was 
earned on every fourth bar press. DMT (3.2 and 10.0 mg/kg) 
and LSD (0.1 mg/kg) given IP with 0.9 % NaC1 pretreatment, 
disrupted food-rewarded FR4 bar pressing. Animals were 
pretreated IP (10-15  min) with predetermined, behaviorally 
noneffective doses of morphine, methadone, naltrexone, and 
the (+)- and (-)-enantiomers of naloxone prior,to receiving 
DMT or LSD. Dose-dependent effects wereshown with 
opioid agonist pretreatment. Morphine (0.32-1.0 mg/kg) 
and methadone (0.32 mg/kg) significantly antagonized the 
bar pressing disruption induced by DMT and LSD. Larger 
doses of morphine (3.2mg/kg) and methadone (1 .0-  
3.2 mg/kg) potentiated only LSD-induced effects, with no 
effect on DMT-treatedgroups. The opioid antagonists ( - ) -  
naloxone and naltrexone potentiated the disruption of bar 
pressing induced by DMT and LSD. Failure of (+)-naloxone 
to potentiate the DMT effects was attributed to a stereo- 
specific opioid antagonist effect of (-)-naloxone. 
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Historically, opioid agonists have been used in treatment of 
schizophrenia and other mental disorders, and numerous 
reports have demonstrated favorable, but inconsistent thera- 
peutic effects in some psychotic patients (Woodward 1844, 
1850; Carlson and Simpson 1963 ; Levinson 1971 ; Wellisch et 
al. 1971; Crow 1976; Comfort 1977a, b; Gold et al. 1977; 
Berken et al. 1978). However, further investigations of the 
therapeutic value of opioid agonists in mental disorders were 
overshadowed by the introduction of neuroleptic drug ther- 
apy (Delay and Deniker 1952), as well as the prevailing social 
and legal attitudes toward the use of opioids. 
The purpose of this study was to further determine 
possible interactions of several opioid agonists and antag- 
onists with DMT and LSD using a simple rodent model in 
which the behavioral effects of hallucinogens are well docu- 
mented. Fertziger and Fischer (1977) reported that naloxone 
pretreatment in the rat shortened the LSD-induced excitatory 
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phase and prolonged the cataleptic phase. In a previous 
investigation we reported that naloxone pretreatment poten- 
tiated DMT- and LSD-induced suppression of food- 
rewarded FR4 behavior in the rat (Ruffing et al. 1979). The 
present report extends these findings to selected relatively 
pure opioid agonists and antagonists. 
Materials and Methods 
Male Holtzman rats at least 90 days old were maintained at 
approximately 70 % of their expected free-feeding weight and 
housed separately in a constant temperature and humidity- 
controlled facility. 
Procedures. To establish food-rewarded bar pressing, rats 
were trained to press a bar daily for 1 h to receive 0.01 ml 
reward of a sugared, evaporated milk solution as positive 
reinforcement. The milk solution was prepared by combining 
400 ml evaporated milk with 400 ml tap water and 60 g 
granulated sugar. The daily bar pressing schedule was fixed 
ratio 4 (FR4), i.e., a reward was earned on every fourth bar 
press. Experiments were conducted in a darkened, isolated 
room using Lehigh Valley Electronics rodent operant test 
cages (model 143-21). Operant behavioral data was collected 
automatically by Gerbrand cumulative recorders, illustrating 
bar pressing rates, reinforcements, and any disruption of 
normal bar pressing behavior during daily sessions. After 
achieving stable FR4 behavior, each rat was assigned daily 
60-min bar pressing sessions for at least 5 days prior to 
injection. Procedures for training and experiment are similar 
to those described by Kovacic et al. (1978). Animals were 
drug-free for a minimum of 10 days prior to the experiment 
and had no past drug history, except for prior DMT and LSD 
administration. Rats were scheduled in randomly assigned 
groups (N = 5-11) ,  while each rat served as its own control 
to compare the effects of a hallucinogen with and without the 
assigned pretreatment drug. Minimum 7-day. drug-free in- 
tervals were observed between scheduled injections and 
control groups were pretreated with 0.9 % NaC1 IP prior to 
the assigned hallucinogen injection. Doses of DMT (3.2 and 
10.0 mg/kg) and LSD (0.1 mg/kg) were administered IP to 
disrupt food-rewarded FR4 bar pressing behavior. The 
pretreatment drugs and doses used in this study were 
morphine sulfate and methadone HC1 (0.32, 1.0, and 
3.2 mg/kg, (+)-naloxone HC1 (3.2 mg/kg), (-)-naloxone HC1 
(1.0 and 3.2mg/kg), and naltrexone HC1 (1.16 and 
3.7 mg/kg). Due to a limited supply of (+)-naloxone, a single 
pretreatment dose was used. The pretreatment drug doses 
described demonstrated no effect on normal bar pressing 
0033-3158/81/0075/0226/$01.00 
227 
behavior for 120-min periods, as predetermined in pilot 
studies. Doses of naltrexone were calculated in equimolar 
concentrations to naloxone. All dose levels refer to free base 
and all drugs were administered IP. 
In the control pretreatment procedures, rats were injected 
IP with 0.9% NaC1, immediately placed in an operant 
chamber for 10-15  min of bar pressing, injected IP with the 
assigned hallucinogen, and returned immediately to the 
operant chamber until the rat recovered and pressed the bar 
steadily at the preinjection control rate for a minimum 60-rain 
period. Animals were observed and behavioral responses 
were recorded for the duration of the drug effects and 60-min 
bar pressing session. 
The drug pretreatment procedures were identical to the 
previously described control pretreatment procedures, but 
substituting assigned drugs for pretreatment injections. 
Behaviorally noneffective doses for pretreatment drugs used 
in this study were predetermined in pilot studies, whereby rats 
(N = 4) were placed in the operant chamber for 15 rain of bar 
pressing, injected IP with the selected pretreatment dose, 
immediately returned to the operant chamber for a 120-min 
bar pressing session (noneffective doses), or until the rat 
recovered (threshold disruptive dose) and bar pressed steadily 
at the preinjection control rate for a minimum 90-min period. 
Data Analysis. The significance of drug effects was de- 
termined from the length of the horizontal line generated by 
the cumulative recorder, illustrating the disruption of bar 
pressing behavior and duration of drug-induced effects. Two- 
tailed Student's t-test paired comparison determinations were 
calculated according to Snedecor (1956), using the value of 
P <  0.05 as significant. 
Drugs. DMT was obtained from Sigma, St. Louis, Missouri, 
and solutions were prepared by dissolving the free base in 1 N 
HC1, adding 0.9% NaC1, and adjusting the acidity with 
0.1 NaOH to render a 4.5 - 5.0 pH for the final volume. LSD- 
25 (Delysid) was obtained from the National Institute on 
Drug Abuse and was administered in 0.9 % NaC1. Morphine 
sulfate was obtained from Pierce (Rockford, IL, 61105) and 
methadone HC1 from Eli Lilly (Indianapolis, IN, 46285) and 
were administered in 0.9 % NaC1. (-)-Naloxone HC1 was 
generously supplied courtesy of the Endo Laboratories 
(Garden City, NY, 11530) and doses were administered in 
0.9% NaC1. (+)-Naloxone HC1 (NIH 9548) was supplied 
courtesy of Dr. Arthur E. Jacobson from the National 
Institute of Health, and was prepared by dissolving the 
compoundin a solution of 0.9 % NaC1 and 0.1 N HC1, adding 
0.1 N NaOH to adjust the acidity of the final volume, 
rendering a 4.3 pH. Naltrexone HC1 was obtained from Endo 
(Labs.) and was administered in 0.9 % NaC1. 
Results 
Cumulative bar pressing records of rats trained on food- 
rewarded FR4 schedules typically show constant high re- 
sponse rates with only a very short post-reinforcement pause, 
followed by the same high response rates (Ferster and Skinner 
1957; Thompson and Schuster 1968). Representative ex- 
amples of cumulative FR4 bar pressing records detailing 
response rates, and the abrupt onset, duration, and termi- 
nation of effects induced by DMT (3.2-10.0 mg/kg) and 
LSD (0.1 mg/kg) have been previously reported (Kovacic and 
Domino 1976; Kovacic et al. 1978). Characteristic gross 
behavioral DMT- and LSD-induced effects were seen within 
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Fig. 1. Mean differences in the dose effect of morphine (left) and 
methadone (right) pretreatment on the duration of DMT- and LSD- 
induced suppression of FR4 bar pressing behavior in the rat. Groups 
(N = 5 - 10) received fixed doses of 3.2 or 10.0 mg/kg DMT or 0.1 mg/kg 
LSD for control and pretreatment injections with each rat serving as its 
own control. Control treatment was NaC1 0.9 % 10-15 min prior to 
DMT or LSD. Predetermined behaviorally noneffective pretreatment 
doses were administered 10-15 min prior to DMT or LSD. Morphine 
(0.32-1.0 mg/kg) and methadone (0.32 mg/kg) pretreatment doses are 
shown to antagonize the effects of DMT- and LSD-induced disruption of 
FR4 behavior, whereas morphine (3.2 mg/kg) and methadone (1.0- 
3.2 mg/kg) potentiated LSD-induced effects, showing no significant 
effect differences in DMT groups. In this and subsequent figures, paired- 
comparison Student's t-tests were used (*P<0.05, **P<0.01, 
*** P < 0.001). Also, all injections were administered IP and numerals in 
parentheses represent the number of animals in designated groups 
2 - 5  min following IP injections. These consisted of pro- 
longed periods of lying quietly in an excessively flattened 
position with eyes open, crawling in a flattened position, jerky 
movements, arching, occasional repetitious head and/or body 
movements, cage circling, muscular twitching, flattening and 
extension of the hind limbs, occasional Straub tail, walking 
backwards, and disinterest in food and/or bar pressing. The 
observed gross behavioral DMT- and LSD-induced effects 
were consistent in all treatment groups, except morphine and 
methadone. Morphine-pretreated rats displayed fewer, and 
markedly reduced gross behavioral effects (i.e., brief periods 
of lying and sitting quietly with minimal flattening, periodic 
interest in food and/or bar pressing, and reduced muscular 
twitching and movement jerkiness). Intensified gross be- 
havioral effects were observed in the methadone-pretreated 
groups (i.e., markedly increased display of flattening, rep- 
etitious head and body movements, Straub tail, and muscular 
twitching). At the cessation of drug effects all rats would 
groom briefly, then abruptly start and continue bar pressing 
at preinjection control rates. 
Figure 1 illustrates biphasic dose effects (expressed as 
mean differences in minutes) of the opiate agonists, morphine 
(left), and methadone (right) at 0.32, 1.0, and 3.2 mg/kg IP 
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Table 1. Mean duration of DMT- and LSD-induced disruption of food-rewarded FR4 bar pressing in control (0.9 % NaCl-pretreated) and 
corresponding opioid agonist- or antagonist-pretreated rats. All pretreatments were at 10-15-rain intervals 
Pretreatment Mean duration of disruption (min + SE) 
(mg/kg IP) 
DMT (3.2 mg/kg) DMT (10 mg/kg) LSD (0.1 mg/kg) 
N Control Drug P" N Control Drug pa N Control Drug P~ 
pretreat- pretreat- pretreat- pretreat- pretreat- pretreat- 
ment ment ment ment ment ment 
Morphine (0.32) 8 26 + 3 15 _+ 4 < 0.05 6 52 _+ 5 54_+ 9 NS 8 31 _+ 2 19 _+ 6 <0.05 
Morphine (1.0) 9 23 _+ 1 8 _+ 4 < 0.01 6 47 + 4 28 + 8 < 0.05 9 39_+ 2 34 + 3 <0.05 
Morphine (3.2) 8 23 + 1 21 _+ 2 NS 10 51 _+ 3 58 _+ 4 NS 6 39 _+ 4 60 _+ 4 <0.01 
Methadone (0.32) 6 28 _+ 3 10 _+ 4 < 0.01 6 50 _+ 3 36 _+ 6 < 0.05 6 31 _+ 2 12 _+ 5 <0.05 
Methadone (1.0) 5 31 _+ 3 29 _+ 7 NS 5 53 + 3 55 + 15 NS 6 29 _+ 2 43 _+ 3 <0.05 
Methadone (3.2) 5 28 _+ 3 32 +_ 8 NS 5 49 _+ 3 57 _+ 12 NS 6 29 _+ 1 56 _+ 13 <0.05 
Naloxone(l.0) 6 24_+ 3 36_+ 4 <0.001 5 36_+ 6 57_+ 10 <0.05 
Naloxone (3.2) 6 19 + 2 41 _+ 7 < 0.005 6 30 _+ 2 62 ___ 5 <0.001 
Naltrexone (1.16) 9 22 + 1 33 _+ 3 < 0.01 6 26 _+ 3 33 +_ 3 <0:05 
Naltrexone (3.7) 8 22 _+ 2 37 + 4 < 0.001 5 26 + 1 37 _+ 4 <0.05 
9 Paired-comparison t-tests 
pretreatment 10--15 min prior to IP DMT (3.2 and 
10.0mg/kg) and LSD (0.1 mg/kg). While significant an- 
tagonism of the DMT- and LSD-induced behavioral sup- 
pressant effects is shown with doses of 0 .32 -1 .0  mg/kg IP 
morphine and 0.32mg/kg IP methadone, 3.2mg/kg IP 
morphine and 1 . 0 -  3.2 mg/kg IP methadone potentiated the 
LSD-induced effects, but  not the DMT effects. Table I shows 
the duration of DMT- and LSD-induced disruption of F R4  
bar pressing (mean _+ SE) for the control (0.9% NaC1- 
pretreated group) and corresponding morphine- or 
methadone-pretreated groups. 
In contrast, pretreatment ( 1 0 - 1 5  rain) with the opioid 
antagonists naloxone (1 .0 -3 .2  mg/kg IP) and equimolar 
naltrexone doses (1 .16-3 .7  mg/kg IP) significantly poten- 
tiated effects of DMT (3.2 mg/kg) and LSD (0.1 mg/kg) on 
behavior, as expressed in mean differences (Fig. 2). Mean 
( +_ SE) durations of disruption of bar pressing for the control 
(0.9 % NaCl-pretreated group) and corresponding naloxone- 
or naltrexone-pretreated group are also shown in Table 1. 
Stereospecific effects of 3.2 mg/kg IP (+)-naloxone and 
3.2mg/kg IP (-)-naloxone (commonly referred to as nal- 
oxone) pretreatment 1 0 - 1 5  min prior to DMT (3.2 mg/kg 
IP) are shown in Fig. 3. No significant DMT-effect differences 
were observed in the (+)-naloxone-pretreated group is con- 
trast to the potentiation of DMT-induced effects observed 
with the (-)-naloxone enantiomer pretreatment. Mean ( + SE) 
durations of cessation of bar pressing for controls and 
corresponding (§ and (-)-naloxone-pretreated groups were : 
0.9%: NaCI-DMT 3.2mg/kg, 24_+ 2, and (+)-naloxone 
3.2-DMT 3.2 mg/kg, 15 -t- 6; 0.9% NaC1-DMT 3.2 mg/kg, 
19 + 2, and ( - ) -na loxone  3.2-DMT 3.2 mg/kg, 41 _+ 7, re- 
spectively. 
Discussion 
The results of the present study extend previous observations 
that naloxone potentiated DMT- and LSD-induced disrup- 
tion of food-rewarded bar pressing in the rat (Ruffing et al. 
1979), as well as recent findings that naloxone additionally 
potentiated the disruptive effects of mescaline (Commissaris 
et al. 1980). It is generally known that the biologically active 
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effects of naloxone (top) and 
naltrexone (bottom) pretreatment on the duration of DMT- and LSD- 
induced suppression of FR4 bar pressing behavior in the rat. Groups 
(N = 5-9) received a fixed dose of DMT (3.2mg/kg) or LSD 
(0.1 mg/kg) for control and pretreatment injections with each rat serving 
as its own control. Graph points represent the mean differences in bar 
pressing disruption time (min) for the control and corresponding 
pretreatment group. Control treatment was 0.9 % NaC110 - 15 min prior 
to DMT or LSD. Predetermined behaviorally noneffective pretreatment 
doses of naloxone (1.0-3.2 mg/kg) and equimolar naltrexone doses 
(1.16- 3.7 mg/kg) were administered 10-15 min prior to DMT or LSD. 
*P< 0.05, **P< 0.01, ***P< 0.001 
narcotic antagonist is the (-)-naloxone isomer (Pert and 
Snyder 1973; Gayton et al. 1978; Iijima et al. 1978; Jacquet 
1980; Herz et al. 1979). Thus, it is of special interest that in the 
present study (+)-naloxone was inactive in potentiating the 
effects of DMT, confirming stereospecificity. 
229 
( + ) - N A L O X O N E  ( - ) - N A L O X O N E  
DMT 3.2 mg/kg [L "~ DMT 3,2 mg/kg 
0 "g~ 
g... 
. 2 o -  . 2 o  
Q. 
Z z 4"10 - +tO 
LL ~ - I O  - (5) - I 0  
z N.S. 




t t  
(6) 
PRETREATMENT DOSE ( 3 . 2  m g / k g )  
Fig. 3. Stereospecific dose effects of (+)- and (-)-naloxone pretreatment on 
the duration of DMT-induced disruption of FR4 bar pressing behavior 
in the rat. Groups of animals (N = 5 - 6) received a fixed dose of DMT 
(3.2 mg/kg) for control and pretreatment injections with each rat serving 
as its own control. Graph points represent the mean differences in bar 
pressing disruption time (min) for the control and corresponding 
pretreatment group. Control treatment was 0.9 ~ NaC110-15 min prior 
to DMT. The pretreatment drug dose [3.2 mg/kg (+)-naloxone], prede- 
termined as behaviorally noneffective, was administered 10-15 min 
prior to DMT. Potentiation of DMT-induced effects is shown in the 
(-)-naloxone isomer pretreatment group (right), with no significant effect 
differences (NS) shown in the (+)-naloxone isomer pretreatment group 
(left). **P< 0.01 
Since pure narcotic antagonists,  such as naloxone and 
naltrexone, potent ia ted the effects of  D M T  and LSD, one 
would expect narcotic agonists, such as morphine and 
methadone,  to have opposite or antagonizing effects. This is 
indeed what  occurred with small to moderate  doses of both  
narcotic agonists, while larger doses of both  narcotics did not  
antagonize the disruptive bar  pressing effects of either D M T  
or LSD, but  actually potent ia ted the LSD-induced effects. 
The data indicate a very impor tant  dose-effect relationship 
not  only for the opioids, but  also for the hallucinogens. For  
example, the larger D M T  dose (10.0 mg/kg), when compared  
to 3.2 mg/kg DMT,  was less effectively antagonized by both 
morphine and methadone.  These dose-effect differences may 
be related to different modes of  D M T  clearance in the brain, 
with 10.0 mg/kg D M T  having the slower rate of clearance, 
since tert iary amines can be weak MAO inhibitors and D M T  
inhibits this enzyme (Carlsson and Lindquist  1972; Lu and 
Domino  1976; Lu et al. 1974). Al though D M T  and LSD 
similarly depress serotonin-containing neurons (Jacobs et al. 
1977), it is known that  LSD addit ionally has dopamine (DA) 
agonist-antagonist  activity (Meltzer et al. 1977; Pieri et al. 
1974; Von Hungen et al. 1974; DaPrada  et al. 1975). Harris  et 
al. (1977) repor ted that  naloxone potent iated the rate- 
decreasing effects of  low doses of D A  agonists like apomor-  
phine and ET-495. While this might explain naloxone poten- 
t iat ion of  LSD, it does not explain the potent ia t ion of  DMT.  
LSD and morphine have been repor ted to antagonize 
certain actions of each other. LSD antagonizes morphine- 
induced analgesia in rats (Dhawan and Gup ta  1959), emesis 
in dogs (Dhawan and Gup ta  1961), and some narcotic actions 
of morphine (Murphree 1965). Conversely, morphine an- 
tagonizes LSD-induced pyrexia in rabbits (Dhawan 1960), 
and LSD-induced hypotension and carot id occlusion re- 
sponse in dogs (Gupta  et al. 1968). A search for the morphine 
crystal pharmacophor ic  pat tern coordinates in other mol- 
ecules, consisting of the aromatic ring and remote nitrogen 
atom, disclosed the identical crystal structure in LSD as an 
impor tant  molecular similarity (Gund 1977). 
It should be noted that  the severity of  gross behavioral  
effects did not  always correlate with the cessation of drug 
effects or onset of  bar  pressing. For  example, methadone 
(0.32 mg/kg) plus D M T  or LSD intensified severe gross 
behavior,  but  showed less suppression of  bar  pressing. 
Currently, much literature exists that  is highly con- 
troversial, regarding the role of  endogenous opiates in mental 
disease, as to whether naloxone antagonizes hallucinations in 
schizophrenic patients, and whether fl-endorphin is thera- 
peutically beneficial (Usdin et al. 1979). The present study 
indicates impor tant  dose-effect relationships that  must be 
taken into account before any sweeping generalizations can 
be made. A possibility for the seemingly contradictory 
findings in rats and humans suggest that  both  physiological 
and pharmacological  interactions may be occurring. 
However, our unpublished results when using a nonopiate  
control  drug such as chlorpromazine,  demonstrate no anta- 
gonism of the effects of  either D M T  or LSD. These results 
indicate that  small doses of  opioids are selective antagonists 
of D M T  and LSD, at least in the rat. Fur ther  studies are 
needed to determine specific peripheral  and central effects of  
hallucinogens and opioid interactions. Especially importan t 
would be a study of  (+)-morphine, a compound devoid of 
narcotic analgesic properties but  said to retain some opioid 
behavioral  effects (Jacquet et al. 1977). The present study 
indicates that  there are important  and generally consistent 
interactions between DMT,  LSD, and opioids in the rat. The 
data  reinforce a possible role of opioids in mental processes 
involving hallucinogenic substances. 
Acknowledgements. A special thank you to Ms. Deborah Ashley for her 
patience in typing the manuscript and to Mr. Bill Reynolds for his 
expertise in drawing the figures. 
Referenees 
Berken GH, Stone MM, Stone SK (1978) Methadone in schizophrenic 
rage: A case study. Am J Psychiatry 135:248-249 
Carlson ET, Simpson MM (1963) Opium as a tranquilizer. Am J 
Psychiatry 120:112 - 117 
Carlsson A, Lindquist M (1972) The effect of L-tryptophan and some 
psychotropic drugs on the formation of 5-hydroxytryptophan in the 
mouse brain in vivo. J Neural Trans 33:23-43 
Comfort A (1977 a) Morphine as antipsychotic drug. Lancet I:95 
Comfort A (1977b) Morphine as an antipsychotic? Clin Toxicol 
11:383-386 
Commissaris RL, Moore KE, Rech RH (1980) Naloxone potentiates the 
disruptive effects of mescaline on operant responding in the rat. 
Pharmacol Biochem Behav 13 : 601 - 603 
Crow T J, Deakin JFW, Johnstone EC, Longden A (1976) Dopamine and 
schizophrenia. Lancet II, 1027 
DaPrada M, Soner A, Burkard W, Batholini G, Pletscher A (1975) 
Lysergic acid diethylamide: Evidence for stimulation of central 
dopamine receptors. Brain Res 94:67-73 
Delay J, Deniker P (1952) Trente-huit cas de psychoses traitees par la cure 
prolongee et continue de 4560 RP. Le Congres des A1. et Neurol. de 
Langue France. In: Compte rendu Congres, p 443, Masson, Paris 
Dhawan BN (1960) Blockade of LSD-25 pyrexia by morphine. Arch Int 
Pharmacodyn Ther 127 : 307 - 313 
Dhawan BN, Gupta GP (1959) LSD-25 antagonism of morphine 
analgesia. Arch Int Pharmacodyn Ther 123:132-139 
Dhawan BN, Gupta GP (1961) Antiemetic activity of d-lysergic acid 
diethylamine. J Pharmacol Exp Ther 133:137-139 
Ferster CB, Skinner BF (1957) Schedules of reinforcement. Appleton 
Century Crofts, New York 
230 
Fertziger A, Fischer R (1977) Interaction between narcotic antagonist 
(naloxone) and lysergic acid diethylamide (LSD) in the rat. 
Psychopharmacology 54:313 - 314 
Gayton RJ, Lambert LA, Bradley PB (1978) Failure of (+)-naloxone to 
antagonize responses to opioid peptides. Neuropharmacology 
17:549-551 
Gold MS, Donabedian RK, Dillard, M Jr, Slobetz FW, Riordan CE, 
Kleber HD (1977) Antipsychotic effect of opiate agonists. Lancet II, 
398- 399 
Gund P (1977) Three-dimensional pharmacophoric pattern searching. 
In: Hahn FE (ed) Progress in molecular and subcellular biology, Vol 
5. Springer, Berlin Heidelberg New York, pp 117-143 
Gupta GP, Dhawan KN, Dhawan BN (1968) Antagonism of central 
vasomotor effects of lysergie acid diethylamide (LSD-25) by mor- 
phine. Jpn J Pharmacol 18:255-259 
Harris RA, Snell D, Loh HH, Way EL (1977) Behavioral interactions 
between naloxone and dopamine agonists. Eur J Pharmacol 
43: 243 - 246 
Herz A, Blasig J, Fry JP, Hollt V, Meyer G, Prezewlocki R (1979) Opiate 
receptors, their endogenous ligands and the development of 
tolerance/dependence. In: Jacob J (ed) Advances in pharmacology 
and therapy, Vol 1. Receptors. Pergamon Press, New York, pp 4 7 -  
57 
Iijima I, Minamikawa J, Jacobson AE, Brossi A, Rice KC (1978) Studies 
in the (+)-morphinan series. 5. Synthesis and biological properties 
of (+)-naloxone. J Med Chem 21:398-400 
Jacobs BL, Trulson ME, Stern WC (1977) Behavioral effects of LSD in 
the cat: Proposal of an animal behavior model for studying the 
actions of hallucinogenic drugs. Brain Res 132:301 - 314 
Jacquet YF (1980) Stereospecific, dose-dependent antagonism by nal- 
oxone of nonopiate behavior in mice. Pharmacol Biochem Behav 
13:585-587 
Jacquet YF, Klee WA, Rice KC, Iijima I, Minawikawa J (1977) Stereo- 
specific and nonstereospecific effects of (+)- and (-)-morphine. 
Evidence for a new class of receptors. Science 198:842- 845 
Kovacic B, Domino EF (1976) Tolerance and limited cross-tolerance to 
the effects of N,N-dimethyltryptamine (DMT) and lysergic acid 
diethylamide-25 (LSD) on food-rewarded bar pressing in the rat. J 
Pharmacol Exp Ther 197:495- 502 
Kovacic B, Lu LJ Wang, Ruffing D, Domino EF (1978) Interactions of 
partial LSD analogs with behavioral disrupting effects of LSD and 
DMT in the rat. Eur J Pharmacol 47:37-44 
Levinson P (1971) Addiction induction: Will it be tested? Perspect Biol 
Med 14:671-674 
Lu LJ, Domino EF (1976) Effects of iproniazid and tranylcypramine on 
the half-life of N,N-dimethyltryptamine in rat brain and liver. 
Biochem Pharmacol 23:1521 - 1527 
Lu LJ, Wilson AE, Moore RH, Domino EF (1974) Correlation between 
brain N,N-dimethyltryptamine (DMT) levels and bar pressing 
behavior in rats: Effect of MAO inhibition. Pharmacologist 
16:237 
Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS (1977) 
Lysergic acid diethylamide: Evidence for stimulation of pituitary 
dopamine receptors. Psychopharmacology 54:39-44 
Murphree HB (1965) Narcotic analgesics. I. Opium alkaloids. In: 
Dipalma JR (ed) Drill's pharmacology in medicine. McGraw Hill, 
New York, pp 252-265 
Pert CB, Snyder SH (1973) Opiate receptor: Demonstration in nervous 
tissue. Science 179:1011 - 1015 
Pieri L, Pieri M, Haefely W (1974) LSD as an agonist of dopamine 
receptors in the striatum. Nature 252:586 588 
Ruffing D, Kovacic B, Demetriou S, Domino EF (1979) Naloxone 
enhancement of DMT- and LSD-25-induced suppression of food- 
rewarded bar pressing behavior in the rat. Psychopharmacology 
62:207-210 
Snedeeor GW (1956) Statistical methods. Iowa State College Press, Ames 
Thompson T, Schuster CR (1968) The classification of behavior. In: 
Behavioral pharmacology. Prentice Hall, Englewood Cliffs, pp 98 - 
136 
Usdin E, Bunney WE, Kline NS, eds (1979) Endorphins in mental health 
research. London, MacMillan 
Von Hungen K, Roberts S, Hill DF (1974) LSD as an agonist and 
antagonist at central dopamine receptors. Nature 252:588-589 
Wellisch DK, Gay GG, Wesson DR, Smith DE (1971) The psychotic 
heroin addict. J Psychedelic Drugs 4 :46-49 
Woodward SB (1844) Twelfth Annual Report of the State Lunatic 
Hospital at Worcester, December 1844. Dutton and Wentworth, 
Boston 
Woodward SB (1850) Observations of medical treatment on insanity. Am 
J Insane 7:1 
Received December 22, 1980; Final version June 22, 1981 
